A Phase I Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Dose-ascending Trial of BAL-30072 in Combination With Meropenem in Healthy Volunteers

Trial Profile

A Phase I Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Dose-ascending Trial of BAL-30072 in Combination With Meropenem in Healthy Volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Jul 2014

At a glance

  • Drugs BAL 30072 (Primary) ; Meropenem
  • Indications Gram-negative infections
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Basilea Pharmaceutica
  • Most Recent Events

    • 22 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top